title: The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
abstract: BACKGROUND
  GH suppression after oral glucose load [oral glucose tolerance test (OGTT)] and normal age- and gender-matched IGF-I levels reflect biochemical control of acromegaly. The OGTT is the gold standard for determining control of GH secretion at diagnosis and after surgical treatment, but the usefulness of performing an OGTT in patients treated with medical therapy has not been determined.
  
  
  OBJECTIVE
  Our objective was to assess relationships between basal GH levels (basal GH), GH responses to OGTT [GH nadir (GHn)], and IGF-I levels.
  
  
  METHODS
  This was a retrospective electronic database review.
  
  
  METHODS
  This study was performed at a tertiary outpatient pituitary center.
  
  
  METHODS
  A total of 166 patients with acromegaly (79 females, 87 males) were included in the study. Four categories of testing were performed: diagnosis, postoperative assessment without medication, testing during somatostatin analog (SA) therapy, and testing during dopamine agonist (DA) therapy.
  
  
  METHODS
  Basal serum GH and IGF-I levels and GH levels 2 h after 75 g OGTT were measured.
  
  
  RESULTS
  A total of 482 simultaneous OGTT and IGF-I measurements were observed from 1985--2008. Discordant results of oral glucose tolerance testing (GHn and IGF-I) were observed 33, 48, and 18% in postoperative assessment without medication, SA, and DA categories, respectively. In the SA category, 42% of tests were discordant with normal IGF-I and nonsuppressed GHn. In contrast, 4% of tests were discordant with normal IGF-I and nonsuppressed GH in those treated with DA. No significant differences in discordance were observed when basal GH was used.
  
  
  CONCLUSIONS
  Both basal and GHn levels are highly discordant with IGF-I levels during medical therapy with SAs. The OGTT is not useful in assessing biochemical control in these subjects.
authors.affiliation: Department of Medicine, Research Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA.
authors.forename: John D
authors.initials: JD
authors.lastname: Carmichael
authors.forename: Vivien S
authors.initials: VS
authors.lastname: Bonert
authors.forename: James M
authors.initials: JM
authors.lastname: Mirocha
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery; D000236:Adenoma / Q000097:blood / Q000175:diagnosis / Q000378:metabolism / Q000601:surgery; D001786:Blood Glucose / Q000378:metabolism*; D003940:Diagnostic Techniques, Endocrine; D005260:Female; D005951:Glucose Tolerance Test; D019382:Human Growth Hormone / Q000032:analysis / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood / Q000175:diagnosis / Q000378:metabolism / Q000601:surgery; D011184:Postoperative Period; D011237:Predictive Value of Tests; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I